The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiorit
about
Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal diseaseReview of meningococcal vaccines with updates on immunization in adultsRandomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial.Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 Years and older: results of an open-label, randomized, controlled trial.Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.Meningococcal polysaccharide A O-acetylation levels do not impact the immunogenicity of the quadrivalent meningococcal tetanus toxoid conjugate vaccine: results from a randomized, controlled phase III study of healthy adults aged 18 to 25 years.Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, ACWY-TT.Quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT): a review.Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review.
P2860
Q27028161-5A1E8246-FF83-4A52-90B8-CC83E470CF43Q28828692-8E1F0719-0058-46EC-94EF-4478B00723B8Q34057733-E37E3232-D9FA-4103-B428-A8F261073C62Q34170021-05A017FD-3C55-4105-BBD1-D6245E8C2FB5Q35799561-2131A1CF-C7E7-449B-9EEC-1D6E0EF422E1Q36791713-F8E9779F-FC44-4BED-9539-58E1D4BA6A64Q37197065-3AE9B52F-4176-493A-B27E-524B8C3609C4Q37252405-D30A4C3F-1C1D-4464-A9A2-8687EA0A1999Q38109830-8F448590-6E48-4918-9128-B945EF7BDD9BQ38118371-FEF95AC5-275C-4CCC-898E-31C29EA4AC12Q38743826-549A1728-CF4B-4EC7-B16A-35668914A2D3Q47672096-3643995D-3F23-4CD5-A67E-B43684069002
P2860
The immunogenicity and safety of an investigational meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (ACWY-TT) compared with a licensed meningococcal tetravalent polysaccharide vaccine: a randomized, controlled non-inferiorit
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
The immunogenicity and safety ...... zed, controlled non-inferiorit
@ast
The immunogenicity and safety ...... zed, controlled non-inferiorit
@en
type
label
The immunogenicity and safety ...... zed, controlled non-inferiorit
@ast
The immunogenicity and safety ...... zed, controlled non-inferiorit
@en
prefLabel
The immunogenicity and safety ...... zed, controlled non-inferiorit
@ast
The immunogenicity and safety ...... zed, controlled non-inferiorit
@en
P2093
P2860
P356
P1476
The immunogenicity and safety ...... zed, controlled non-inferiorit
@en
P2093
Efren Dimaano
Ghassan Dbaibo
Jacqueline Miller
Mari Rose Aplasca-De Los Reyes
Noel Macalalad
Veronique Bianco
Yaela Baine
P2860
P304
P356
10.4161/HV.20211
P577
2012-04-09T00:00:00Z